溶解性环氧化酶缺乏症通过向细胞染色体P450 2E1的方法,可以挽救心力衰竭与保存的喷射分数
Min Zhang1, Chen Chen2, Xinxing Liu3
1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; School of pharmacy, Hainan Medical University (Hainan Academy of Medical Sciences), Haikou 571199, China; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.
Journal of molecular and cellular cardiology
|November 17, 2025
概括
可溶性环氧化酶 (sEH) 抑制改善了在代谢和机械应激诱导的心力衰竭中心脏功能,并保留了喷射分数 (HFpEF). 准sEH可以恢复保护性环氧乙酸 (EETs),并改善心脏功能障碍.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 之前的研究将可溶性环氧化酶 (sEH) 活性与心力衰竭的死亡率与保存的喷射分数 (HFpEF) 联系起来.
- 在代谢和机械压力诱导的HFpEF中,sEH/epoxyeicosatrienoic acid (EETs) 轴在代谢和机械压力诱导的HFpEF中的作用以前是未知的.
研究的目的:
- 在"双击"HFpEF小鼠模型中研究sEH和EET的功能和机制.
- 探索sEH作为HFpEF的潜在治疗点.
主要方法:
- 使用"双击"的HFpEF小鼠模型,结合高脂肪饮食和氧化合成酶抑制.
- 采用兰根多夫系统用于心肌细胞隔离和复合腺相关病毒 (AAV9) 进行基因传递.
- 研究了细胞染色体P450 2E1 (CYP2E1) 在sEH抑制剂疗效中的作用.
主要成果:
- 在HFpEF模型中,sEH活动和表达升高,而EETs水平降低.
- 在K191的脱化中,在HFpEF中保持了SEH活性.
- 基因或药理上的sEH抑制恢复了EETs,改善了透缩功能障碍和心脏重塑,部分是通过向CYP2E1来减少活性氧物种 (ROS) 和脂肪酸吸收.
结论:
- 对于由代谢和机械压力引起的HFpEF,sEH是一个可行的治疗标.
- EETs的心脏保护作用,部分通过向CYP2E1进行调解,为HFpEF患者提出了新的治疗策略.
相关概念视频
01:30Heart Failure V: Medical Management
204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
01:29Heart Failure II: Pathophysiology
693
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
693
01:30Cardiomyopathy II: Dilated Cardiomyopathy
449
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
449
01:29Cardiomyopathy V: Interprofessional Care
316
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
316
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K